Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406),
Two-year results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406), van de Bent M